Highlights:
– 17 children dead, six critical: Acute renal failure linked to Coldrif cough syrup claims young lives in Maharashtra and Madhya Pradesh.
– Toxic culprit identified: Tests confirm diethylene glycol (DEG) contamination in Coldrif, a banned batch from Sresan Pharmaceuticals.
– Nationwide crackdown: Multiple states ban the syrup, seize stocks, and probe related medicines like Anset and Nextro-DS.
– Legal action intensifies: FIRs filed against manufacturer and prescribing doctors; production halted at Tamil Nadu facility.
– Global alarm sounded: WHO seeks export details, flags risks of substandard drugs in children under six.
In a heartbreaking escalation of a public health crisis gripping central India, the death toll from a contaminated cough syrup has climbed to 17 young lives lost, with six more children clinging to survival in hospitals across Nagpur. The victims, all under the age of five, succumbed to acute renal failure after being prescribed Coldrif, a seemingly innocuous remedy for common cold symptoms that has been revealed to harbor a deadly toxin.
Among the deceased is Divyansh Suryavanshi, a bright-eyed three-year-old from Madhya Pradesh’s Chhindwara district, whose father, Nilesh Suryavanshi, watched helplessly as his son deteriorated following a routine dose of the syrup. “He just had a little cough,” Nilesh recounted, clutching an empty Coldrif bottle outside the Government Medical College and Hospital (GMCH) here. “We trusted the doctor. Now, he’s gone, and I don’t know how to face the emptiness.”
The outbreak, which began surfacing in late August, has exposed glaring lapses in India’s pharmaceutical oversight, echoing a series of global scandals involving toxic formulations. Laboratory tests conducted by Tamil Nadu’s Drugs Control Department confirmed that Coldrif, manufactured by Sresan Pharmaceuticals in Kancheepuram district, was adulterated with diethylene glycol (DEG)—a cheap, industrial solvent nearly 500 times above permissible limits. DEG, commonly used in antifreeze and brake fluids, is notorious for its nephrotoxic effects, particularly devastating in children whose developing kidneys offer little defense against such poisons.
The crisis originated in Chhindwara, a rural pocket of Madhya Pradesh bordering Maharashtra, where at least 11 children perished in the initial wave. As symptoms worsened—fever giving way to vomiting, anuria, and organ shutdown—desperate families ferried their little ones across state lines to Nagpur’s specialized pediatric units. Six more deaths followed in GMCH and private facilities like Colors Hospital and Nelson Hospital, bringing the confirmed toll to 17. The six hospitalized survivors, transferred from Chhindwara, remain in critical condition, some hooked to dialysis machines after innovative interventions with Fomepizole, an antidote typically reserved for methanol poisoning.
Dr. Manish Tiwari, head of pediatrics at GMCH Nagpur, described the grim scene: “These children arrived in multi-organ failure, their tiny bodies overwhelmed by the toxin. Standard treatments failed until we pivoted to Fomepizole in consultation with national experts. It’s a race against time, but we’ve stabilized three so far.” Biopsies from the deceased revealed irreversible kidney damage laced with DEG crystals, underscoring the syrup’s role as the common thread.
The scandal has ignited a nationwide crackdown. Madhya Pradesh was the first to ban Coldrif on October 4, swiftly followed by Maharashtra’s FDA issuing a statewide “stop-use” alert on October 5 for Batch No. SR-13 (manufactured May 2025, expiry April 2027). States including Rajasthan, Punjab, Kerala, Tamil Nadu, Uttar Pradesh, and Jharkhand have imposed similar prohibitions, with multi-agency raids seizing stocks from pharmacies and warehouses. In Nagpur, local authorities have extended scrutiny to other suspect syrups like Anset and Nextro-DS, prompted by family testimonies and tip-offs.
Sresan Pharmaceuticals faces mounting legal heat. Tamil Nadu halted production after its own tests deemed the batch “adulterated and substandard.” An FIR has been lodged against the firm and implicated doctors, including Chhindwara practitioner Dr. Praveen Soni, charged with negligence under Bharatiya Nyaya Sanhita Section 276 for prescribing the unverified medication. “This is not just a manufacturing error; it’s systemic negligence,” said a senior Madhya Pradesh health official, who spoke on condition of anonymity. Preliminary probes suggest cost-cutting measures led to DEG substitution for the pricier, safe propylene glycol.
The World Health Organization (WHO) has amplified global alarm, urging India for details on potential exports of Coldrif and assessing the need for a worldwide medical products alert. “This tragedy underscores persistent gaps in substandard drug surveillance,” WHO spokesperson Dr. Margaret Harris stated in Geneva. “We reiterate: cough and cold medicines should be avoided in children under six unless absolutely necessary.” The agency referenced prior DEG crises, from Gambia’s 2022 child deaths to Uzbekistan’s 2023 outbreak, all tied to Indian-sourced syrups.
India’s Union Health Ministry, under fire for delayed response, has dispatched Central Drugs Standard Control Organisation (CDSCO) teams for spot checks. Initial ministry tests cleared unrelated samples, but critics decry the opacity. “Why did it take child funerals to trigger action?” demanded opposition leader Rahul Gandhi in Parliament, calling for a special probe. Health Minister J.P. Nadda countered with promises of stricter good manufacturing practices and expedited recalls, emphasizing that over 1,000 drug units nationwide are now under audit.
As Nagpur’s corridors echo with muffled sobs, families like the Suryavanshis grapple with unimaginable loss. “Divyansh loved chasing butterflies in our village yard,” Nilesh whispered. “A simple cold shouldn’t steal that.” For the survivors, the path to recovery is fraught, but their resilience offers a flicker of hope amid the outrage.
This incident, unfolding against India’s ambitious pharmaceutical export boom—valued at $25 billion annually—serves as a stark reminder of the human cost when profit eclipses safety. As investigations deepen, one question lingers: How many more “cures” lurk as concealed killers in medicine cabinets across the nation?
